课题基金 / 基金详情

项目摘要

项目成果

Shirley Wang的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 随机对照试验(RCT)被认为是评估治疗效果的金标准。 然而,典型随机对照试验的两个特点限制了它们对患者、提供者和其他决策者的实用性。 首先,随机对照试验通常侧重于狭窄的患者群体,以提高内部有效性。这限制了 随机对照试验会导致年龄较大和病情较重的目标人群,特别是在治疗效果不同的情况下。 是存在的。其次,许多随机对照试验的随访时间很短,尽管他们评估的许多治疗方法是 打算长期使用。尽管随机对照试验在研究期间提供了关于治疗效果的证据 随访中,估计治疗的长期影响是困难的。随着患者年龄的增长,他们的疾病状态可能 改变,他们会形成新的和恶化的情况,改变治疗的效果。因此, 随机对照试验中观察到的平均治疗效果可能不能准确反映长期治疗情况。 结果。由于这些限制而缺乏概括性,导致在将RCT结果翻译为 临床实践,特别是在上市后早期阶段。迫切需要开发出各种方法 这可以使试验结果对患者、临床医生和其他决策者更有用。我们提议写一部小说 在存在的情况下,将随机对照试验结果扩展到更广泛的患者群体并持续更长时间的方法 就是这样。该方法使用来自个人级别RCT数据的关于hte的证据和个人级别的 用于估计适用于外部目标人群特征的影响的模拟模型,例如 年纪较大的个体。来自三个具有里程碑意义的RCT的现有个人水平数据将作为案例研究,以 评估将随机对照试验结果推广到老年患者的可行性和应用 现有医疗保险数据确定:长期抗凝治疗(RE-R)的随机评估 LY)试验,ARNI和ACEI的前瞻性比较,以确定对全球死亡率和 心力衰竭的发病率(PAGAME-HF),以及与Valsartan相比,LCZ696的有效性和安全性 射血分数保留的心力衰竭患者的发病率和死亡率(Paragon-HF)。我们的 假说是随机对照试验中有关hte的信息可以用来预测治疗结果。 与随机对照试验中研究的相比,目标人口更多,时间更长。
英文摘要
Project Summary/Abstract Randomized controlled trials (RCTs) are considered the gold standard for assessing efficacy of treatments. However, two characteristics of typical RCTs limit their utility for patient, providers, and other decision-makers. First, RCTs often focus on narrow patient populations to increase internal validity. This limits generalizability of the RCT results to older and sicker target populations, especially when heterogeneity of treatment effect (HTE) is present. Second, many RCTs have short follow-up even though many treatments that they evaluate are intended to be used for a long time. Although RCTs provide evidence about treatment efficacy during the study follow-up, estimating the long-term impact of treatment is difficult. As patients age, their disease state can change and they can develop new and worsening conditions that modify the effect of a treatment. Therefore, the average treatment effect observed during an RCT may not accurately reflect long-term treatment outcomes. Lack of generalizability due to these limitations causes uncertainty in translating RCT findings in clinical practice, especially in the early post-marketing stages. There is an urgent need to develop methods that can make trial results more useful to patients, clinicians, and other decision-makers. We propose a novel approach to expand RCT results to broader patient populations and over longer periods in the presence of HTE. The approach uses evidence about HTE derived from individual-level RCT data and an individual-level simulation model to estimate effects applicable to the characteristics of external target populations, such as older individuals. Existing individual-level data from three landmark RCTs will be used as case studies to evaluate the feasibility and application of the proposed approach for generalizing RCT results to older patients identified in existing Medicare data: the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE- LY) trial, the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF), and the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF). Our hypothesis is that information about HTE in the RCTs can be leveraged to predict treatment outcomes in a larger target population and over longer time periods than studied in the RCTs.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Mathematical and computational modeling of suicidal thoughts and behaviors
  • 批准号:
    10437592
  • 项目类别:
  • 资助金额:
    $3.28万
  • 财政年份:
    2021
  • 负责人:
    Shirley Wang
  • 依托单位:
Understanding effectiveness of new drugs in older adults shortly after market entry
  • 批准号:
    9908033
  • 项目类别:
  • 资助金额:
    $36.41万
  • 财政年份:
    2018
  • 负责人:
    Shirley Wang
  • 依托单位:
Ethical Issues in Prescribing Drugs to Older Adults for Whom Representative Randomized Trial Data Is Lacking
  • 批准号:
    10366434
  • 项目类别:
  • 资助金额:
    $17.84万
  • 财政年份:
    2018
  • 负责人:
    Shirley Wang
  • 依托单位:
Understanding effectiveness of new drugs in older adults shortly after market entry
  • 批准号:
    10133498
  • 项目类别:
  • 资助金额:
    $36.56万
  • 财政年份:
    2018
  • 负责人:
    Shirley Wang
  • 依托单位:
海外基金